Toluene → tert-butyl (1'-benzyl-1-(5-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)spiro[indoline-3,4'-piperidine]-4-yl)methylcarbamate

HRID 529144ノート

反応式

HRID 529144 の反応式
[CH2:1]([N:8]1[CH2:13][CH2:12][C:11]2([C:21]3[C:16](=[CH:17][CH:18]=[CH:19][C:20]=3[CH2:22][NH:23][C:24](=[O:30])[O:25][C:26]([CH3:29])([CH3:28])[CH3:27])[NH:15][CH2:14]2)[CH2:10][CH2:9]1)[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1.CC1(C)C2C(=C(P(C3C=CC=CC=3)C3C=CC=CC=3)C=CC=2)OC2C(P(C3C=CC=CC=3)C3C=CC=CC=3)=CC=CC1=2.C([O-])([O-])=O.[Cs+].[Cs+].C1(C)C=CC=CC=1.Cl[C:87]1[C:88]2[CH:95]([CH2:96][CH3:97])[CH2:94][CH2:93][C:89]=2[N:90]=[CH:91][N:92]=1>CC([O-])=O.CC([O-])=O.[Pd+2]>[CH2:1]([N:8]1[CH2:13][CH2:12][C:11]2([C:21]3[C:16](=[CH:17][CH:18]=[CH:19][C:20]=3[CH2:22][NH:23][C:24](=[O:30])[O:25][C:26]([CH3:27])([CH3:29])[CH3:28])[N:15]([C:87]3[C:88]4[CH:95]([CH2:96][CH3:97])[CH2:94][CH2:93][C:89]=4[N:90]=[CH:91][N:92]=3)[CH2:14]2)[CH2:10][CH2:9]1)[C:2]1[CH:3]=[CH:4][CH:5]=[CH:6][CH:7]=1

参加物

7

反応物 5

HCID 1140TolueneHCID 10796Cesium carbonateHCID 6360441,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine)HCID 86651806Tert-butyl (1'-benzylspiro[indoline-3,4'-piperidine]-4-yl)methylcarbamateHCID 866518114-chloro-5-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine

生成物 1

HCID 86651812tert-butyl (1'-benzyl-1-(5-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)spiro[indoline-3,4'-piperidine]-4-yl)methylcarbamate収率 70%

試薬・触媒・溶媒 1

HCID 167845palladium(II) acetate触媒

反応条件

温度
95 °C

実験手順

A 3-neck round bottom flask was charged with tert-butyl (1′-benzylspiro[indoline-3,4′-piperidine]-4-yl)methylcarbamate (446 mg, 1.09 mmol; see Example 27, Step 3), Pd(OAc)2 (24.6 mg, 0.109 mmol), Xantphos (95 mg, 0.164 mmol) and Cs2CO3 (536 mg, 1.64 mmol) and purged with N2. Toluene (6 mL, 0.547 mmol; sparged with N2 for 30 minutes) and 4-chloro-5-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine (200 mg, 1.09 mmol) were injected into the reaction, and the reaction was heated to 95° C. for 24 hours. LCMS showed most of the starting material had been consumed. The reaction was cooled, mixed with EtOAc and filtered through glass filter paper. The filtrate was concentrated to a residue and purified by silica gel chromatography (gradient: 5-50% (80 DCM: 19 MeOH: 1 NH4OH)/DCM). Purification provided tert-butyl (1′-benzyl-1-(5-ethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)spiro[indoline-3,4′-piperidine]-4-yl)methylcarbamate (422 mg, 0.762 mmol, 70% yield). 1H NMR (CDCl3, 400 MHz) δ 8.62 (s, 1H), 7.29-7.35 (m, 5H), 7.25 (m, 1H), 7.16 (t, 1H), 6.91 (d, 1H), 4.54 (br.s, 1H), 4.20-4.30 (m, 3H), 3.97 (m, 2H), 3.53 (s, 2H), 3.27 (m, 1H), 2.85-2.97 (m, 4H), 2.51 (m, 1H), 2.26 (m, 1H), 2.11 (d, 2H), 2.04 (t, 1H), 1.85 (m, 1H), 1.75 (d, 1H), 1.59 (d, 1H), 1.46 (s, 9H), 1.18 (m, 1H), 0.77 (t, 3H). MS (APCI+) [M+H]: 554.2.

後処理

  1. custompurged with N2
  2. customhad been consumed
  3. temperatureThe reaction was cooled
  4. additionmixed with EtOAc
  5. filtrationfiltered through glass
  6. filtrationfilter paper
  7. concentrationThe filtrate was concentrated to a residue
  8. custompurified by silica gel chromatography (gradient: 5-50% (80 DCM: 19 MeOH: 1 NH4OH)/DCM)
  9. customPurification

出典と根拠

ORDレコード
ord-37865e4351984ec0b0947358b8453ad6
出典データセット
uspto-grants-2016_05
特許番号
US09346805B2

反応ノート

読み込み中…